ArticleFrontiers in oncology2012
Anti-idiotypic antibodies as cancer vaccines: achievements and future improvements.
Article in Frontiers in oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 52 citations in OpenAlex.
- Prospects of anti-GD2 immunotherapy for retinoblastoma.Frontiers in immunology · 2024Review
- GD2-targeting therapy: a comparative analysis of approaches and promising directions.Frontiers in immunology · 2024Review
- Potential of an anti-bevacizumab idiotype scFv DNA-based immunization to elicit VEGF-binding antibody response.Gene therapy · 2023Article
- IgG autoantibodies against ACE2 in SARS-CoV-2 infected patients.Journal of medical virology · 2023Article
- Article
- Immunomodulatory potential of anti-idiotypic antibodies for the treatment of autoimmune diseases.Future science OA · 2020Review
- Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy.Frontiers in oncology · 2020Review
- Technological Innovations in Disease Management: Text Mining US Patent Data From 1995 to 2017.Journal of medical Internet research · 2019Article
- CD20-Mimotope Peptides: A Model to Define the Molecular Basis of Epitope Spreading.International journal of molecular sciences · 2019Article
- Osmolytes in vaccine production, flocculation and storage: a critical review.Human vaccines & immunotherapeutics · 2019Review
- Tumor-Associated Disialylated Glycosphingolipid Antigen-Revealing Antibodies Found in Melanoma Patients' Immunoglobulin Repertoire Suggest a Two-Direction Regulation Mechanism Between Immune B Cells and the Tumor.Frontiers in immunology · 2019Article
- The Promise of Anti-idiotype Revisited.Frontiers in immunology · 2019Review
- The role of proteomics in the age of immunotherapies.Mammalian genome : official journal of the International Mammalian Genome Society · 2018Review
- Methods for improving the immunogenicity and efficacy of cancer vaccines.Expert opinion on biological therapy · 2018Review
- Towards personalized, tumour-specific, therapeutic vaccines for cancer.Nature reviews. Immunology · 2018Review
- Semi-synthetic vNAR libraries screened against therapeutic antibodies primarily deliver anti-idiotypic binders.Scientific reports · 2017Article
- Intimal hyperplasia induced by vascular intervention causes lipoprotein retention and accelerated atherosclerosis.Physiological reports · 2017Article
- TargetingJournal of immunology research · 2017Review
- Anti-bevacizumab idiotype antibody vaccination is effective in inducing vascular endothelial growth factor-binding response, impairing tumor outgrowth.Cancer science · 2016Article
- Anti-cancer vaccines - a one-hit wonder?The Yale journal of biology and medicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the discovery of tumor-associated antigens (TAAs), researchers have tried to develop immune-based anti-cancer therapies. Thanks to their specificity, monoclonal antibodies (mAbs) offer the major advantage to induce fewer side effects than those caused by non-specific conventional treatments (e.g., chemotherapy, radiotherapy). Passive immunotherapy by means of mAbs or cytokines has proved efficacy in oncology and validated the use of immune-based agents as part of anti-cancer treatment options. The next step was to try to induce an active immune protection aiming to boost own's host immune defense against TAAs. Cancer vaccines are thus developed to specifically induce active immune protection targeting only tumor cells while preserving normal tissues from a non-specific toxicity. But, as most of TAAs are self antigens, an immune tolerance against them exists representing a barrier to effective vaccination against these oncoproteins. One promising approach to break this immune tolerance consists in the use of anti-idiotypic (anti-Id) mAbs, so called Ab2, as antigen surrogates. This vaccination strategy allows also immunization against non-proteic antigens (such as carbohydrates). In some clinical studies, anti-Id cancer vaccines indeed induced efficient humoral and/or cellular immune responses associated with clinical benefit. This review article will focus on recent achievements of anti-Id mAbs use as cancer vaccines in solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.